{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:47:11Z","timestamp":1787010431660,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Severe acute respiratory syndrome coronavirus 2 is associated with high mortality among transplant recipients. Comparative data that define humoral responses to the Oxford-AstraZeneca (AZ) and BNT162b2 (Pfizer-BioNTech) vaccines are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>We recruited 920 kidney transplant patients receiving at least 1 dose of severe acute respiratory syndrome coronavirus 2 vaccine, excluding patients with virus pre-exposure. Serological status was determined with the COVID-SeroKlir ELISA (Kantaro-EKF Diagnostics). Patients with a corrected antibody level of &lt;0.7 AU\/mL were considered seronegative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      Four hundred ninety-five AZ and 141 Pfizer patients had a sample analyzed after first dose and 593 after second dose (346 AZ versus 247 Pfizer). After first dose, 25.7% of patients seroconverted (26.6% AZ, 22.8% Pfizer). After second dose, 148 (42.8%) of AZ seroconverted compared with 130 (52.6%) of Pfizer (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.02; hazard ratio, 1.48; 95% confidence interval, 1.07-2.06). When negative responders were excluded, Pfizer patients were shown to have significantly higher response than AZ patients (median 2.6 versus 1.78 AU\/mL,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.005).\n                    <\/jats:p>\n                    <jats:p>\n                      Patients on mycophenolate had a reduced seroconversion rate (42.2% versus 61.4%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001; hazard ratio, 2.17) and reduced antibody levels (0.47 versus 1.22 AU\/mL,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.001), and this effect was dose dependent (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.05). Prednisolone reduced the seroconversion from 58.2% to 43.6% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.03) among Pfizer but not AZ recipients. Regression analysis showed that antibody levels were reduced by older age (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.002), mycophenolate (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), AZ vaccine (versus Pfizer,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.001), and male gender (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.02). Sixteen of 17 serious postvaccine infections occurred to patients who did not seroconvert.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Both seroconversion and antibody levels are lower in AZ compared with Pfizer vaccinated recipients following 2 vaccine doses. Mycophenolate was associated with lower antibody responses in a dose-dependent manner. Serious postvaccine infections occurred among seronegative recipients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000004105","type":"journal-article","created":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T23:00:31Z","timestamp":1647212431000},"page":"1421-1429","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["An Analysis of Serological Response and Infection Outcomes Following Oxford-AstraZeneca (AZD1222) and Pfizer-BioNTech (mRNA BNT162b2) SARS-CoV-2 Vaccines in Kidney and Kidney-pancreas Transplants"],"prefix":"10.1097","volume":"106","author":[{"given":"Argiris","family":"Asderakis","sequence":"first","affiliation":[{"name":"Cardiff Transplant Unit, University Hospital of Wales, Cardiff, United Kingdom."},{"name":"Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Khalid","sequence":"additional","affiliation":[{"name":"Cardiff Transplant Unit, University Hospital of Wales, Cardiff, United Kingdom."},{"name":"Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Koimtzis","sequence":"additional","affiliation":[{"name":"Cardiff Transplant Unit, University Hospital of Wales, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Ponsford","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom."},{"name":"Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Szabo","sequence":"additional","affiliation":[{"name":"Cardiff Transplant Unit, University Hospital of Wales, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chalklin","sequence":"additional","affiliation":[{"name":"Cardiff Transplant Unit, University Hospital of Wales, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Bramhall","sequence":"additional","affiliation":[{"name":"Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Grant","sequence":"additional","affiliation":[{"name":"Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Moat","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Immunology, and Toxicology, University Hospital of Wales, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian R.","family":"Humphreys","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Jolles","sequence":"additional","affiliation":[{"name":"Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"103355","DOI":"10.1016\/j.ebiom.2021.103355","article-title":"Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: a consecutive case series.","volume":"67","author":"Truong","year":"2021","journal-title":"EBioMedicine"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0166-3542(83)90013-X","article-title":"Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients.","volume":"3","author":"Grob","year":"1983","journal-title":"Antiviral Res"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1016\/j.vaccine.2007.08.031","article-title":"Solid organ transplantation and response to vaccination.","volume":"25","author":"Serrano","year":"2007","journal-title":"Vaccine"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/jlts.2000.8313","article-title":"Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list.","volume":"6","author":"Dom\u00ednguez","year":"2000","journal-title":"Liver Transpl"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1600-6143.2007.02066.x","article-title":"Influenza vaccination is efficacious and safe in renal transplant recipients.","volume":"8","author":"Scharp\u00e9","year":"2008","journal-title":"Am J Transplant"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1183\/09031936.01.00215201","article-title":"The humoral immune response to influenza vaccination in lung transplant patients.","volume":"18","author":"Mazzone","year":"2001","journal-title":"Eur Respir J"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1111\/j.1600-6143.2011.03753.x","article-title":"Influenza vaccination in the organ transplant recipient: review and summary recommendations.","volume":"11","author":"Kumar","year":"2011","journal-title":"Am J Transplant"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.kint.2021.04.005","article-title":"Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine.","volume":"99","author":"Benotmane","year":"2021","journal-title":"Kidney Int"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jama.2021.4385","article-title":"Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients.","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/TP.0000000000003654","article-title":"Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients.","volume":"105","author":"Boyarsky","year":"2021","journal-title":"Transplantation"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients.","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1097\/TP.0000000000003818","article-title":"Very low immunization rate in kidney transplant recipients after one dose of the BNT162b2 vaccine: beware not to lower the guard!","volume":"105","author":"Georgery","year":"2021","journal-title":"Transplantation"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1097\/TP.0000000000003889","article-title":"Humoral response of renal transplant recipients to the BNT162b2 SARS-CoV-2 mRNA vaccine using both RBD IgG and neutralizing antibodies.","volume":"105","author":"Hod","year":"2021","journal-title":"Transplantation"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1097\/TP.0000000000003780","article-title":"Safety and reactogenicity of 2 doses of SARS-CoV-2 vaccination in solid organ transplant recipients.","volume":"105","author":"Ou","year":"2021","journal-title":"Transplantation"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abd7728","article-title":"Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.","volume":"370","author":"Wajnberg","year":"2020","journal-title":"Science"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","article-title":"A serological assay to detect SARS-CoV-2 seroconversion in humans.","volume":"26","author":"Amanat","year":"2020","journal-title":"Nat Med"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/ajt.16615","article-title":"Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus.","volume":"21","author":"Grupper","year":"2021","journal-title":"Am J Transplant"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1111\/ajt.16710","article-title":"Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: not alarming, but should be taken gravely.","volume":"21","author":"Grupper","year":"2021","journal-title":"Am J Transplant"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1097\/TP.0000000000003850","article-title":"Antibody response to the Janssen COVID-19 vaccine in solid organ transplant recipients.","volume":"105","author":"Boyarsky","year":"2021","journal-title":"Transplantation"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.202003-0527LE","article-title":"Lung recruitability in COVID-19-associated acute respiratory distress syndrome: a single-center observational study.","volume":"201","author":"Pan","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19.","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1111\/ajt.16570","article-title":"SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients.","volume":"21","author":"Fav\u00e0","year":"2021","journal-title":"Am J Transplant"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/TP.0000000000004059","article-title":"Real-world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against SARS-CoV-2 in solid organ and islet transplant recipients.","volume":"106","author":"Callaghan","year":"2022","journal-title":"Transplantation"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/TP.0000000000004064","article-title":"Simple vaccination is not enough for the transplant recipient.","volume":"106","author":"Chapman","year":"2022","journal-title":"Transplantation"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with Covid-19 (RECOVERY): a randomised, controlled, open-label, platform trial.","volume":"399","year":"2022","journal-title":"Lancet"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T12:11:50Z","timestamp":1749298310000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004105","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,8]]}}}